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Abstract: 
Neurotoxicity linked to excessive brain manganese levels can occur as a result of high level Mn exposures 
and/or metabolic aberrations (liver disease and decreased biliary excretion). Increased brain manganese levels 
have been reported to induce oxidative stress, as well as alterations in neurotransmitter metabolism with 
concurrent neurobehavioral and motor deficits. Two putative mechanisms in which manganese can produce 
oxidative stress in the brain are: (1) via its oxidation of dopamine, and (2) interference with normal 
mitochondrial respiration. Measurements of antioxidant species (e.g., glutathione and metallothionein), and the 
abundance of proteins (enzymes) exquisitely sensitive to oxidation (e.g., glutamine synthetase) have been 
commonly used as biomarkers of oxidative stress, particularly in rat brain tissue. This paper examines the link 
between manganese neurotoxicity in the rat brain and common pathways to oxidative stress. 




1.1. Manganese neurotoxicity 
Manganese is an essential nutrient and it is important for optimal cellular function. However, exceedingly high 
brain manganese concentrations are known to cause neurotoxicity (Cotzias et al., 1968). Manganese has been 
implicated in oxidative stress (Stokes et al., 2000; DeSole et al., 1997), as well as disturbance of 
neurotransmitter metabolism (Miele et al., 2000; Montes et al., 2001). Few reports exist on brain manganese 
concentrations upon manganese intoxication. The concentrations of manganese in human striatum and globus 
pallidus (primary target areas) are unknown. Cerebellar concentrations of manganese are available from 
Japanese accident victims, and at the time of autopsy they ranged between 9 and 10 µM (Sumino et al., 1975). 
However, these values are likely lower than those in the striatum and globus pallidus, both of which are known 
to accumulate more manganese than cerebellum. A study performed almost three decades ago examined 
manganese concentration in striatum and globus pallidus (two regions in the nonhuman primate known to 
accumulate manganese) of monkeys dosed for 3 months with manganese dioxide (Suzuki et al., 1975). Striatal 
manganese concentration reached 264 µM, while manganese concentration in globus pallidus peaked at 334 
µM. In rats, manganese concentrations can reach up to 200 µM depending upon the brain region and dosing 
regiment (Ingersoll et al., 1999; Lai et al., 1999; Roels et al., 1997). Thus, during manganese toxicity, it is 
possible for brain levels to exceed 350 µM. Manganese concentrations in various parts of the rat striatum have 
been reported to range from 4.4 to 18 µM, and in exposed rats, the levels of manganese in the striatum increase 
to 23–70 µM (Ingersoll et al., 1999; Lai et al., 1999; Roels et al., 1997). Notably, these studies suggest that both 
in primates and rodents, homeostatic control of brain manganese concentrations is tight, because even in 
conditions of high exposures, levels of brain manganese increase only by several fold (3–4). 
 
The manganese from MMT is in the form of several aerosolized salts when it is combusted. The most abundant 
species represented by manganese phosphate and manganese sulfate (Lynam et al., 1999; Zayed et al., 1999). 
Pharmacokinetic studies have shown that the salt characteristics will determine the rate of transport into the 
brain with the following rank order: MnCl2>MnSO4>MnPO4 (Drown et al., 1986; Dorman et al., 2001). 
Nonetheless, it is important to note that regardless of exposure, once absorbed and within biological media (e.g., 
blood, cerebrospinal fluid), manganese would be expected to bind to the same ligands and behave in an 
analogous pharmacokinetic fashion. Thus, the physical and chemical properties of these aerosolized salts will 
only govern their absorption and elimination properties, but overall the tissue distribution and their mechanisms 
of toxicity would be expected to be similar, yet on a differential temporal scale (e.g., attainment of toxic 
concentrations of manganese in target tissue would be reached faster for the more soluble manganese salts). 
 
Manganese neurotoxicity (manganism) shares neurological symptoms with several clinical disorders commonly 
described as ―extrapyramidal motor system dysfunction‖, and in particular, Parkinson’s disease (PD) (Calne et 
al., 1994). Evidence for the involvement of oxidative stress in the etiology of PD exists, supported by the 
following observations: (1) Monoamine oxidase (MAO) activity, which catabolizes intraneuronal dopamine and 
yields hydrogen peroxide (H2O2), increases with age (Fahn and Cohen, 1992). (2) Pharmacological 
manipulations that enhance dopamine turnover cause an increase in oxidized glutathione (GSH), which can be 
suppressed by simultaneous treatment with the MAO inhibitors clorgyline and deprenyl, indicating that MAO 
activity is a source of oxidative stress (Cohen and Spina, 1989). (3) In postmortem studies of PD brains, the 
activity of glutathione peroxidase and the amounts of glutathione (GSH) in the substantia nigra are reduced 
(Riederer et al., 1989). (4) Oxidative stress is one of the proximate causes of 1-methyl-4- phenyl-1,2,3,6-
tetrahyrdopyridine (MPTP)-induced dopaminergic neuronal degeneration, and transgenic mice overexpressing 
copper/zinc superoxide dismutase are resistant to the neurotoxic action of MPTP (Przedborski et al., 1992). 
 
1.2. Oxidative stress 
Oxidative stress has been implicated as a contributing mechanism by which manganese can be toxic to cells 
(Galvani et al., 1995; Aschner, 1997). A potential mechanism for manganese-induced oxidative stress is via the 
oxidation of dopamine and other catecholamines (Sloot et al., 1996). This is likely because in primates, 
manganese accumulates in dopamine-rich regions, especially in the basal ganglia (Newland, 1999). Another 
possibility is that sequestration of manganese in mitochondria interferes with proper respiration, thereby leading 
to excessive production of reactive oxygen species (ROS). Small initial amounts of oxygen can be self-
propagating via damage to the electron transport chain in mitochondria. When proteins or quinones that 
participate in transfer of electrons are damaged, the chain begins to donate electrons directly to molecular 
oxygen, thereby creating the highly reactive superoxide radical. This leak of electrons to form superoxide is 
most commonly reported at complex I (Blake et al., 1997; Bautista et al., 2000). 
 
Galvani et al. (1995) reported inhibition of complex I of the electron transport chain after treatment of PC12 cell 
cultures with MnCl2. Divalent manganese treatment in HeLa cells was shown to increase in the production of 
ROS (peroxides), and to induce manganese superoxide dismutase and catalase activities without an effect on the 
Cu,Zn-superoxide dismutase level (Oubrahim et al., 2001). Gavin et al. (1999) showed evidence suggesting that 
the ATPase complex is inhibited at very low levels of mitochondrial manganese, and that complex I is inhibited 
only at higher manganese concentrations. In agreement with the earlier suggestion of Tyree and Archibald and 
Tyree (1987) and the findings of Ali et al. (1995), Chen et al. (2001) demonstrated that trivalent manganese is 
more potent at inhibiting complex I, but the divalent form is the predominant species within cells and is largely 
bound to ATP. Nevertheless, manganese in any oxidation state will likely spontaneously give rise to 
infinitesimal amounts of trivalent manganese, and HaMai et al. (2001) demonstrated that even at trace amounts, 
trivalent manganese can cause formation of ROS. They also showed evidence that divalent manganese fails to 
induce oxidative effects. Finally, a recent report showed that exposure of dopaminergic cells to MMT resulted 
in rapid increases in ROS followed by mitochondrial-induced apoptosis (Anantharam et al., 2002). However, 
because combustion of MMT in cars yields various manganese salts, direct exposure of cells to MMT does not 
seem to represent a toxicologically relevant experimental model, and it is not germane to a discussion on the 
neurotoxicity of inorganic manganese. 
 
Notably, other studies have failed to support ROS generation and oxidative stress as a result of exposure to 
manganese. Brenneman et al. (1999) examined the effect of orally [0, 25, or 50 mg/kg/day of MnCl2 from 
postnatal day (PND) 1 to 49] administered manganese on brain function in developing CD rats. The high-dose 
manganese exposure was associated with increased spontaneous motor activity on PND 21 and ROS levels (8-
hydroxy-2' -deoxyguanosine) were elevated in cerebellum but not striatum, the latter representing the primary 
target site in primates. Additional studies showed that iron sulfate, copper sulfate, vanadyl sulfate, cobalt 
sulfate, nickel sulfate, and zinc sulfate generate ROS (formation of malondialdehyde) in aqueous extracts of 
National Institute of Standards and Technology (NIST) ambient particulate matter and diesel engine particles, 
but that manganese failed to do so (oral communication, Lynam). Furthermore, it has been shown that low 
concentrations of divalent manganese protect cells against oxidative stress and that this protective effect derives 
from the fact that manganese can catalyze the dismutation of superoxide radical anions and H2O2 under 
physiological conditions (Oubrahim et al., 2001). 
 
Astrocytes take up glutamate by a Na
+
-dependent mechanism (Hertz, 1979). In the presence of ammonia, 
glutamate is metabolized to glutamine by the astrocyte-specific enzyme glutamine synthetase (GS; Martinez-
Hernandez et al., 1977), maintaining [glutamate]Ο at 0.3 µM (Waniewski and Martin, 1986). This represents a 
10,000-fold gradient vs. [glutamate]i (3 mM). This glutamate–glutamine pathway constitutes the source of a 
glutamate pool in brain (Berl et al., 1961). GS contains eight manganese ions per octamer, and accounts for 
approximately 80% of total manganese in brain. Unlike neurons, astrocytes have the ability to concentrate 
manganese at levels 50-fold higher than the culture media (Wedler et al., 1989; Aschner et al., 1992), providing 
a mechanism by which manganese concentrations in astrocytic cytosol could attain the range required for 
activation of GS. Recent studies in our laboratory (Erikson and Aschner, 2002; Erikson et al., 2002) and others 
(Hazell and Norenberg, 1997) have demonstrated that glutamate uptake is significantly attenuated in primary 
astrocyte cultures upon addition of manganese to the culture medium. Lafon-Cazal et al. (1993) showed that 
glutamate receptor (NMDA) stimulation produces significant elevations in both superoxide and hydroxyl 
radicals in cultured cerebellar granule cells. Interference with glutamate transporter function will lead to 
increased extracellular glutamate concentrations. Potential ROS generation as a consequence of manganese 
exposure will further oppose the removal of extracellular glutamate by inhibiting the high affinity glutamate 
transporters (Trotti et al., 1998). The cumulative sum of these events will trigger an amplifying cycle, 
potentially contributing to the dysfunction of astrocytes and their inability to maintain optimal control over the 
extracellular milieu, thereby indirectly leading to neuronal demise via NMDA receptor activation. 
 
1.3. Biomarkers of oxidative stress 
Oxidative stress can be measured by detection of different chemical species. Dichlorofluroescein (DCF) is 
useful for detecting oxygen radicals via a fluorescence-producing reaction. Ali et al. (1995) demonstrated that 
manganese injected in vivo and exposure of brain regions to manganese in vitro both resulted in detection of 
RO5 by DCF fluorescence. A limitation of this method is that living cells are required for analysis. 
Measurement of products directly related to RO5 is also a practical method for assessing oxidative stress in 
tissue. Examples include the measurement of oxidative damage in DNA (comet assay), lipid [thiobarbituric acid 
reactive species (TBAR5)] and protein (glutathione peroxidase activity). However, inconsistency between 
methods has been problematic. Another approach for detection of oxidants is to measure the levels of 
antioxidants [glutathione (G5H) or metallothionein (MT)], as well as the abundance of proteins [glutamine 
synthetase (G5)] that are exquisitely sensitive to oxidative stress. 
 
The tripeptide G5H (γ-glutamylcysteinylglycine) is a major antioxidant in mammalian cells constituting nearly 
90% of the intracellular non-protein thiols (Anderson and Meister, 1983). It is important in maintaining the 
intracellular redox status of protein thiols, for protection against endogenous and exogenous sources of 
oxidative stress, and for the conjugation and excretion of toxic molecules (Meister, 1988,1991). 
 
The MTs, a class of cysteine-containing intracellular proteins, are highly conserved and are widely distributed 
throughout all cells in an organism. They are an important metal binding protein, with zinc serving as the 
primary regulator of MT metabolism in cells (Andrews, 1990; Dunn et al., 1987; Hamer, 1986). Evidence 
suggests that MT acts as an antioxidant by neutralizing RO5 both systemically and in the brain. In situ 
hybridization studies showed that bacterial endotoxin induces MT gene expression (Itano et al., 1991). 
Oxidative stress, kainic acid, and 6-hydroxydopamine, a known dopaminergic toxin and RO5 generator, 
induced MT-I gene expression in the brain (5hiraga et al., 1993). Likewise, compounds (e.g., diquat) that 
generate free oxygen species via the redox cycling increase MT in tissue, along with compounds (e.g., 3-
methylindole) that cause lipid peroxidation, and compounds (e.g., diamide and di-methyl maleate) that deplete 
cellular defense mechanisms (Bauman et al., 1991). 
 
Within the CN5, G5 is exclusively expressed in astrocytes (Martinez-Hernandez et al., 1977). A manganese-
dependent enzyme, G5 catalyzes the formation of glutamine from glutamate. This glutamine is taken up by 
neighboring glutamatergic or γ-aminobutyric acid (GABA-ergic) neurons and deamination back to glutamate 
occurs. This process is considered the primary glutamate-recycling pathway (Van den Berg and Garfinkel, 
1971; Westergaard et al., 1995; Ottersen et al., 1992). Inhibition of G5 activity can have serious consequences 
on neuronal functioning (e.g., decreased glutamate and GABA levels and the inability to detoxify ammonia). 
Given its high susceptibility to oxidation, and subsequent rapid degradation, G5 serves as an excellent marker 
for the presence of RO5 in the brain (5tadtman, 1992). 
 
2. Results and discussion 
Given the above, two recent studies in our laboratory have examined the relationship between manganese 
exposure and oxidative stress in rat brain tissues. The first study employed oral administration of manganese 
chloride (MnCl2) (0, 25, and 50 mg/ kg) to rat neonates throughout the lactational period (postnatal days, PND 
0–21) (Dorman et al., 2000; Weber et al., 2002), and the second study investigated the effects of inhaled 
manganese sulfate (MnSO4) (0, 0.03, 0.3, 3.0 mg Mn/m
3
) for 6 h/day for 14 days on adult rats (PND 70) 
(Dorman et al., 2001; Dobson et al., 2003). 
 
Due to differences in study protocols and design, and limitations in tissue availability the neonatal study was 
restricted to investigating oxidative stress biomarkers in the cortex and cerebellum (Weber et al., 2002). The 
inhalation study (adult rat) was broader and included the striatum, olfactory bulb, hypothalamus, hippocampus, 
and cerebellum (Dobson et al., 2003). Accordingly, direct comparisons between the two studies are limited, and 
the discussion of the results is focused on the effects of manganese exposure on oxidative stress biomarkers 
only within the cerebellum. 
 
A 50 mg/kg oral manganese caused a significant increase in cerebellar manganese concentrations in neonatal 
rats (Dorman et al., 2000), and there was a slight, albeit not statistically significant, increase in cerebellar 
manganese concentration upon inhalation of 3.0 mg Mn/m
3
 in adult rats (Dorman et al., 2001) (Fig. 1). Given 
differences in exposure paradigms (oral vs. inhaled) and differences in total administered doses, the two studies 
cannot be directly compared in terms of net brain manganese accumulation. Nevertheless, the magnitude of 
increased manganese brain concentrations is greater in the neonatal cohort, corroborating earlier observation 
that the developing brain takes up a significant proportion of the manganese retained by the body during the 
early neonatal period. 
 
For example, Keen et al. (1986) have reported that approximately 8% of the total oral manganese dose is 
retained in the neonatal rat brain, exceeding the retention in the adult CNS. Known pharmacokinetic processes 
that may contribute to the increased tissue concentrations and susceptibility of neonatal animals to manganese-
induced neurotoxicity include increased manganese absorption from the gastrointestinal tract, an incompletely 
formed blood–brain barrier, and the virtual absence of biliary manganese excretory mechanisms until weaning 
(Ballatori et al., 1987; Rehnberg et al., 1982; Miller et al., 1975). The relative higher net increase in brain 
manganese concentrations in the neonatal vs. adult brain (Fig. 1) should not necessarily be construed as 
evidence for heightened neurotoxicity in developing animals, given the known requirement for manganese for 
optimal CNS development in the neonate. Manganese concentration in the brain of developing rats is highest of 
all age groups, suggesting that manganese is required in a high amount during infancy, and that a sufficient 
manganese supply is critical for normal brain development (Takeda et al., 1999). The high uptake of manganese 
into the brain of neonatal rats reflects blood concentrations of manganese that are threefold higher than in adults 





Increased GS mRNA expression in the cerebellum of both PND 21 rats (high dose exposure) and PND 70 rats 
(low and high dose exposures) exposed to manganese was observed (Fig. 2) (Dobson et al., 2003; Weber et al., 
2002). This increased GS mRNA expression at the high dose in the PND 21 rats correlated with increased 
cerebellar manganese concentration (Fig. 1). There was no effect of manganese on cerebellar GS protein levels 
in either study (Fig. 3), nor was there any significant effect on total GSH levels in the cerebellum of manganese 
exposed rats (Fig. 4). Finally, manganese exposure in both studies did not significantly affect MT mRNA 




These studies demonstrate that both of these routes of exposure, oral and inhaled (neonatal and adult rats, 
respectively), led to minimal biochemical changes indicative of manganese-induced oxidative stress in 
cerebellar tissues. The only ensuing change in response to manganese exposures was an increase GS mRNA (in 
both cohorts), but notably, GS protein levels were unchanged, suggesting that posttranslational process maintain 
adequate GS protein expression. Accordingly, in the cerebellum, manganese treatment does not appear to inflict 
functional damage that is correlated with the generation of oxidative stress. 
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